{"id":9074,"date":"2020-04-07T16:30:00","date_gmt":"2020-04-07T14:30:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/"},"modified":"2020-04-07T16:30:00","modified_gmt":"2020-04-07T14:30:00","slug":"irlab-publicerar-arsredovisning-for-2019","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/","title":{"rendered":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r r\u00e4kenskaps\u00e5ret 2019 har publicerats och nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.<\/strong><\/div>\n

\u201dVi har nu tv\u00e5 l\u00e4kemedelskandidater med nya verkningsmekanismer som har levererat mycket positiva resultat i Fas IIa-studier vid Parkinson. Detta bekr\u00e4ftar innovationsh\u00f6jden i v\u00e5r forskningsplattform ISP. Vi g\u00e5r\u00a0<\/span><\/span><\/span><\/span><\/span>nu in i \u201ddevelop for launch\u201d-fas med mesdopetam och IRL752 och forts\u00e4tter utvecklingen av v\u00e5ra prekliniska projekt mot Fas I-studier\u201d, s\u00e4ger Nicholas Waters, vd.<\/span><\/span><\/span><\/span><\/span><\/p>\n

IRLAB:s<\/span><\/span><\/span><\/span> \u00e5rsredovisning f\u00f6r 201<\/span><\/span><\/span><\/span>9 bifogas detta pressmeddelande och finns ocks\u00e5 <\/span><\/span><\/span><\/span>tillg\u00e4nglig som nedladdningsbar pdf p\u00e5 <\/span><\/span><\/span><\/span>f\u00f6ljande adress: <\/span><\/span><\/span><\/span>www.irlab.se\/investor-relations\/financial-reports\/<\/span><\/a>.<\/span><\/span><\/span><\/p>\n

\n

F\u00f6r mer information<\/span><\/span><\/strong><\/p>\n

Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
\nTel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
\nE-post: nicholas.waters@irlab.se<\/a><\/span><\/p>\n

Viktor Siewertz, CFO\u00a0
\nTel: +46 727 10 70 70\u00a0
\nE-post: viktor.siewertz@irlab.se<\/a><\/span><\/p>\n<\/div>\n

\n

Om IRLAB<\/span><\/span><\/strong><\/p>\n

IRLAB \u00e4r ett svenskt forsknings- och l\u00e4kemedelsutvecklingsbolag som fokuserar p\u00e5 att utveckla nya l\u00e4kemedel f\u00f6r behandling vid Parkinsons sjukdom. Bolagets l\u00e4ngst framskridna l\u00e4kemedelskandidater, mesdopetam (IRL790) och IRL752, vilka b\u00e5da genomg\u00e5tt Fas IIa-studier, \u00e4r avsedda f\u00f6r behandling av n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinsons sjukdom: ofrivilliga r\u00f6relser (PD-LIDs), psykos (PD-P) och symtom som \u00e4r kopplade till kognitiv f\u00f6rs\u00e4mring s\u00e5som f\u00f6rs\u00e4mrad balans och \u00f6kad risk f\u00f6r fall (PD-Fall). Genom den propriet\u00e4ra forskningsplattformen ISP (Integrative Screening Process) uppt\u00e4cker och utvecklar IRLAB l\u00e4kemedelskandidater f\u00f6r sjukdomar relaterade till det centrala nervsystemet (CNS) d\u00e4r stora v\u00e4xande medicinska behov f\u00f6religger. F\u00f6rutom de kliniska kandidaterna har ISP-plattformen dessutom genererat flera CNS-program som nu \u00e4r i preklinisk fas. IRLAB:s Certified Adviser p\u00e5 Nasdaq First North Premier Growth Market \u00e4r FNCA Sweden AB, info@fnca.se, 08-528 00 399. Mer information p\u00e5 www.irlab.se<\/a>.<\/span><\/span><\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r r\u00e4kenskaps\u00e5ret 2019 har publicerats och nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.<\/p>\n","protected":false},"template":"","class_list":["post-9074","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-regulatory-vpml_sv"],"acf":[],"yoast_head":"\nIRLAB publicerar \u00e5rsredovisning f\u00f6r 2019 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r r\u00e4kenskaps\u00e5ret 2019 har publicerats och nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/\",\"name\":\"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2020-04-07T14:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019 - IRLAB","og_description":"IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r r\u00e4kenskaps\u00e5ret 2019 har publicerats och nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/","name":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2020-04-07T14:30:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2019"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}